The Effectiveness of Salvage Treatments for Recurrent Lesions of Oligodendrogliomas Previously Treated with Upfront Chemotherapy.

[1]  Hideo Nakamura,et al.  Prognostic relevance of genetic alterations in diffuse lower-grade gliomas , 2018, Neuro-oncology.

[2]  R. Spetzler,et al.  Impact of removed tumor volume and location on patient outcome in glioblastoma , 2017, Journal of Neuro-Oncology.

[3]  Susan M. Chang,et al.  Diffuse Infiltrating Oligodendroglioma and Astrocytoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  H. Aburatani,et al.  Genetic and epigenetic stability of oligodendrogliomas at recurrence , 2017, Acta neuropathologica communications.

[5]  L. Nie,et al.  IDH1/2 gene hotspot mutations in central nervous system tumours: analysis of 922 Chinese patients. , 2016, Pathology.

[6]  Satoshi O. Suzuki,et al.  Deferred radiotherapy and upfront procarbazine–ACNU–vincristine administration for 1p19q codeleted oligodendroglial tumors are associated with favorable outcome without compromising patient performance, regardless of WHO grade , 2016, OncoTargets and therapy.

[7]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[8]  Walter J. Curran,et al.  Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. , 2016, The New England journal of medicine.

[9]  Pieter Wesseling,et al.  Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial. , 2016, Neuro-oncology.

[10]  A. Vortmeyer,et al.  Integrated genomic characterization of IDH1-mutant glioma malignant progression , 2015, Nature Genetics.

[11]  Chul-Kee Park,et al.  IDH2 mutation in gliomas including novel mutation , 2015, Neuropathology : official journal of the Japanese Society of Neuropathology.

[12]  M. Mehta,et al.  The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria , 2014, Neuro-oncology.

[13]  D. Pearson,et al.  Prognostic and predictive markers in recurrent high grade glioma; results from the BR12 randomised trial , 2014, Acta neuropathologica communications.

[14]  Caterina Giannini,et al.  Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Steven J. M. Jones,et al.  Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma , 2014, Science.

[16]  W. Mason,et al.  Anaplastic Oligodendroglioma: Advances and Treatment Options , 2013, Current Treatment Options in Neurology.

[17]  E. Shaw,et al.  Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Wei Wu,et al.  Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers , 2012, The Journal of pathology.

[19]  Mitchel S Berger,et al.  An extent of resection threshold for newly diagnosed glioblastomas. , 2011, Journal of neurosurgery.

[20]  O. Chinot,et al.  Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis , 2010, Acta Neuropathologica.

[21]  M. Nikiforova,et al.  Detection of IDH1 and IDH2 mutations by fluorescence melting curve analysis as a diagnostic tool for brain biopsies. , 2010, The Journal of molecular diagnostics : JMD.

[22]  Rui Huang,et al.  Glioma-derived mutations in IDH: from mechanism to potential therapy. , 2010, Biochemical and biophysical research communications.

[23]  Susan M. Chang,et al.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Pieter Wesseling,et al.  IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group , 2010, Clinical Cancer Research.

[25]  Christian Mawrin,et al.  Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas , 2009, Acta Neuropathologica.

[26]  Y. Nishino,et al.  Predictive factors for overall and progression-free survival, and dissemination in oligodendroglial tumors , 2009, Journal of Neuro-Oncology.

[27]  M. Chamberlain,et al.  Bevacizumab for recurrent alkylator‐refractory anaplastic oligodendroglioma , 2009, Cancer.

[28]  M. J. van den Bent,et al.  Oligodendrogliomas: molecular biology and treatment. , 2009, The oncologist.

[29]  Satoshi O. Suzuki,et al.  Prevalence of copy-number neutral LOH in glioblastomas revealed by genomewide analysis of laser-microdissected tissues. , 2008, Neuro-oncology.

[30]  M. Chamberlain,et al.  CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma , 2008, Journal of Neuro-Oncology.

[31]  Tchoyoson C. C. Lim,et al.  Disseminated spread of recurrent oligodendroglioma (WHO Grade II) , 2006, Journal of Clinical Neuroscience.

[32]  M. Piérart,et al.  Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial , 2005, The Lancet.

[33]  J. Menten,et al.  Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas , 2004, Neurology.

[34]  O. Chinot,et al.  Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  Hong Zhao,et al.  Loss of heterozygosity 1p/19q and survival in glioma: a meta-analysis. , 2014, Neuro-oncology.

[36]  Robert J Dempsey,et al.  Science Times , 2022 .